IIMMUNO—FER—GUARD: Immunotherapy-based Modality Using Dendritic cells Loaded with FERroptotic cancer Lysates - Guarding against Glioblastoma and Melanoma Ghent University
The median survival of patients diagnosed with glioblastoma is 12–15 months, with a five-year survival rate of 5%, and cutaneous melanoma is responsible for 80% of deaths from dermatological cancer. Therefore, there is an urgent need to develop novel patient-adjusted anticancer immunotherapies that actively stimulate antitumor T cells, generate long- term memory, and result in significant clinical benefits. Dendritic cells (DCs) vaccines are ...